<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>BOA Biomedical — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<header class="site-header"><h1>Prospect Detail</h1></header>
<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Digital Health</span>
    <h1>53. BOA Biomedical</h1>
    <p class="meta">Pathogen Capture Technology</p>
  </div>
  <div class="section"><h3>1. Startup Name</h3><p><strong>BOA Biomedical</strong></p></div>
  <div class="section"><h3>2. Founder Contact</h3><p><strong>Wyss Institute Team</strong></p><p>Wyss Institute for Biologically Inspired Engineering at Harvard</p><p>Spun out of Wyss Institute research programs</p></div>
  <div class="section"><h3>3. Product Overview</h3><p>BOA Biomedical develops pathogen-capture technology that removes bacteria, viruses, and toxins directly from the bloodstream. The technology uses engineered binding proteins to capture pathogens in a blood filtration device, potentially treating sepsis and other life-threatening infections.</p></div>
  <div class="section"><h3>4. Funding Stage</h3><p><strong>Early Stage</strong> — Developing technology through Wyss Institute support and early venture funding.</p></div>
  <div class="section"><h3>5. How I Found the Company</h3><p>Discovered through Wyss Institute spinout company portfolio and sepsis treatment innovation coverage.</p></div>
  <div class="strengths-weaknesses">
    <div class="section"><h3>Strengths</h3><ul><li><strong>Urgent clinical need:</strong> Sepsis kills 270,000+ Americans annually with limited treatment options.</li><li><strong>Novel mechanism:</strong> Physical removal of pathogens complements antibiotic therapy.</li></ul></div>
    <div class="section"><h3>Weaknesses</h3><ul><li><strong>Complex device:</strong> Blood filtration devices require intensive clinical validation.</li><li><strong>ICU adoption:</strong> Critical care settings have high barriers to new technology adoption.</li></ul></div>
  </div>
  <div class="section"><h3>7. Five Questions for the Team</h3><ol class="questions-list"><li>What pathogens can your device capture and at what efficiency?</li><li>Where are you in the clinical trial process?</li><li>How do you integrate with existing dialysis and blood filtration infrastructure?</li><li>What is the cost per treatment and how does it compare to standard sepsis care?</li><li>Are you pursuing FDA breakthrough device designation?</li></ol></div>
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>
</body>
</html>
